Clinical Trial Detail

NCT ID NCT02627963
Title A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors AVEO Pharmaceuticals, Inc.
Indications

renal cell carcinoma

Therapies

Sorafenib

Tivozanib

Age Groups: adult

No variant requirements are available.